Tegoprazan-d6
Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H+/K+-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C20H13D6F2N3O3
- Masse moléculaire:393.42
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Tegoprazan (1.0 mM and 3.0 mM, 4 h) reduces DSS-induced colitis by maintaining high junction integrity of the epithelial mucosa in Caco-2 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Caco-2 cells
-
Concentration:1.0 mM and 3.0 mM
-
Incubation Time:4 h
-
Result:Protected the intestinal epithelial tight junction barrier and inhibits the increase in intestinal permeability.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Pylorus-Ligated Rats[2]
-
Dosage:3 mg/kg and 10 mg/kg
-
Administration:p.o., a single dose
-
Result:Inhibited basal gastric acid secretion in a dose-dependent manner and was effective at a single dose in Pylorus-Ligated rats.
-
Animal Model:Naproxen-induced acute gastric ulcer rat model[2]
-
Dosage:0.1, 1 and 10 mg/kg
-
Administration:p.o., a single day or daily for 5 days
-
Result:Exerted an antiulcer effect in a dose-dependent manner and was effective at a single dose in naproxen-induced acute gastric ulcer rat model.
-
Animal Model:DNBS and Tegoprazan-induced rats[2]
-
Dosage:30 mg/kg
-
Administration:p.o., twice daily for 5 days
-
Result:Reduced mRNA expression levels of proinflammatory cytokines, especially interleukin-17 (IL17) in DNBS and Tegoprazan-induced rats.
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
Unlabeled Cas 942195-55-3
-
Masse moléculaire 393.42
-
Formule C20H13D6F2N3O3
-
SMILES
CC1=NC2=C(C=C(C=C2N1)C(N(C([2H])([2H])[2H])C([2H])([2H])[2H])=O)O[C@H]3CCOC4=C3C(F)=CC(F)=C4
-
Synonyms
CJ-12420-d6; RQ-00000004-d6
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Tegoprazan-d6 Related Classifications
HY-17623S Related Classifications
Powered by Bioz